Pathologic complete response rates improved with the neoadjuvant and adjuvant treatment of pembrolizumab in TNBC patients

Bookmark and Share
Published: 18 Dec 2019
Views: 272
Prof Peter Schmid - St Bartholomew's Hospital London, London, UK

Prof Peter Schmid gives a press conference at the 2019 San Antonio Breast Cancer Symposium about the neoadjuvant and adjuvant treatment with pembrolizumab in patients with triple-negative breast cancer (TNBC) with lymph node treatment.

Prof Schmid provides updated results from the KEYNOTE-522 trial.

Watch our interview with Prof Peter Schmid here

Read more about the study here